Skip to content

Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge

Improving Both Health in Women With the Use of Osteo-Buddy to Enhance Osteoporosis Knowledge - A Mixed Method Clinical Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07034131
Enrollment
80
Registered
2025-06-24
Start date
2025-07-31
Completion date
2026-03-31
Last updated
2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Postmenopausal, Osteoporosis Risk

Brief summary

This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.

Detailed description

This study will involve evaluating the preliminary effectiveness and feasibility outcomes of the use of Osteo-Buddy, a Virtual Health Assistant (VHA), in improving the knowledge of osteoporosis in women aged 50 and above.

Interventions

OTHEROsteo-Buddy

Osteo-Buddy is a Virtual Health Assistant (VHA) accessible on mobile phones that helps users with: 1. Evaluating their risk level of osteoporosis 2. Recommending screening and referrals 3. Lifestyle interventions through motivation, education and tailored guidance As a 24/7 VHA, it offers real-time, personalised advice based on user inputs and health data.

OTHERUsual Care

Access to digitalised educational materials on osteoporosis, titled 'Healthy Bones'

Sponsors

SingHealth Polyclinics
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 50 and above * Medium or high Osteoporosis Self-Assessment Tool for Asians (OSTA) score * Not undertaken Bone Mineral Density (BMD) scan * Never been treated with anti-osteoporosis medications such as bisphosphonates (e.g. alendronate, risendronate, ibandronate, zolendronate, pamidronate) or denosumab * Able to read and speak English * Currently use and own a smartphone where Osteo-Buddy can be used

Exclusion criteria

* Known terminal illness * Visual, hearing and/or cognitive impairment or mental illness that renders them unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Osteoporosis Prevention and Awareness Tool (OPAAT) scoreOn enrolment and 6-8 weeks post enrolment* 30-item questionnaire measuring osteoporosis knowledge * Minimum value = 0, maximum value = 30 * Higher scores indicate a better outcome
System Usability Scale (SUS)6-8 weeks post enrolment* 10-item questionnaire assessing usability * Minimum value = 0, maximum value = 100 * Higher scores mean a better outcome

Secondary

MeasureTime frameDescription
Recruitment rateover the course of recruitment, estimated 3-4 monthsPercentage of participants successfully recruited among referred participants
Retention rate6-8 weeks post-enrolmentPercentage of recruited participants who complete the study (return for 2nd visit and successfully complete 2nd questionnaire)
Utility rate4 weeksPercentage of intervention arm participants who utilise Osteo-Buddy over the 4 weeks

Contacts

Primary ContactEunice Lim
eunice.lim.s.m@singhealth.com.sg+65 6340 7436

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026